Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zanolimumab: Amended Phase III

GEN amended an ongoing open-label, dose-escalation Phase III trial in 92 patients with mycosis fungoides (MF)

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE